1. The Future of B-Cell Therapies in MS and NMOSD
  2. Targeting the Innate Immune System in PMS
  3. Development and Use of Biomarkers
  4. MRI Measures of Atrophy in the Clinic


OPEN FORUM (with Lunch)*

Thursday, 1 November 2018
Grand Ballroom, Level B
11:30-12:30 Open Forum:
General Principles for the Treatment of MS and NMOSD in the PACTRIMS Region

*Delegates must indicate their attendance to the Secretariat at



Thursday, 1 November 2018
Grand Ballroom, Level B
13:00-14:30 European Charcot Foundation Symposium
Are Disease Phenotypes Still Valuable in the Treatment of MS?
14:30-15:00 Coffee Break
15:00-15:15 Opening Ceremony
15:15-17:10 Opening Lecture SeriesOpening Lecture-1
1. Innate Immune System-Mediated Mechanisms of action in Progressive MS: How to Target Innate Immunity in the Future
– Francisco Javier Quintana (USA)
Opening Lecture-2
2. Alteration of Innate Gamma Delta T Cells and Adaptive Alpha Beta T Cells in Asian MS
– Noriko Isobe (Japan)
Opening Lecture-3
3. Demyelinating Disease in the MENA region
– Bassem Yamout (Lebanon)
17:10-17:30 Coffee Break
17:30-19:00 Merck Sponsored Symposium
19:30-21:00 Welcome Reception


Friday, 2 November 2018
Grand Ballroom, Level B
08:00-09:30 Sanofi Genzyme Sponsored Symposium
09:30-10:00 Coffee Break
10:00-10:45 Oral Presentation-1
10:45-11:30 Oral Presentation-2
11:30-12:00 Two Minute Oral Presentation of Selected Posters
12:00-13:00 Lunch
13:00-14:30 Main Symposium-1
Monitoring of Demyelinating Disease Activity, Treatment Response, and Outcomes
1. Keynote Lecture: Do Clinicians Need to Monitor Atrophy Rates and What Factors Limit the Measurement of Atrophy Rates in the Clinic
– Arman Eshaghi (UK)
2. Passive and Active Monitoring Applications and Devices
– Helmut Butzkueven (Australia)
3. Artificial Intelligence in the Monitoring and Management of MS
– Fu-Dong Shi (China)
14:30-15:10 Coffee Break
15:10-17:10 Main Symposium-2
Biomarkers for Inflammatory CNS Demyelinating Disease Based on the Disease Mechanism
1. Serum Biomarkers for MS Related to Inflammatory and Degenerating Processes
– David Leppert (Switzerland)
2. CSF Biomarkers for NMOSD
– Shuhei Nishiyama (Japan)
3. MRI Markers that Differentiate NMOSD from MS
– Yaou Liu (China)
4. OCT and Eye Movement Markers to Monitor MS Disease Activity
– Owen White (Australia)
17:10-17:30 Coffee Break
17:30-19:00 Biogen Sponsored Symposium
20:00-22:30 Presidential Dinner


Friday, 2 November 2018
Heritage Room, Level G (Breakout Session)
15:10-17:10 Main Symposium-3
Biomarkers for Inflammatory CNS Demyelinating Disease Based on the Disease Mechanism
1. Practical Issues in the Management of Relapsing Inflammatory CNS Diseases in the Asia-Pacific Region
– Shanthi Viswanathan (Malaysia)
2. Aggressive MS & NMOSD: How to Define and How to Manage It
– Ho Jin Kim (Republic of Korea)
3. The Approach to the Management of Indeterminate MS/NMOSD
– Kazuo Fujihara (Japan)
4. Symptomatic Management of MS: What Works and What Doesn’t
– Simon Broadley (Australia)


Saturday, 3 November 2018
Grand Ballroom, Level B
08:00-09:30 Roche Sponsored Symposium
09:30-10:00 Coffee Break
10:00-12:10 Main Symposium-4
Immune Mechanisms and Next Generation Monoclonal Antibody Therapies in MS and Allied Disorders
1. Keynote Lecture: Landscape of B Cell Therapies and Possible Mechanisms of Action in MS
– Heinz Wiendl (Germany)
2. Anti-IL6 Receptor Monoclonal Antibody Therapy in NMOSD
– Manabu Araki (Japan)
3. Anti-C-C Chemokine Receptor 4 Monoclonal Antibody Therapy in Human T-Lymphotropic Virus Type 1-Associated Myelopathy (HAM)
– Yoshihisa Yamano (Japan)
12:10-12:25 Closing and Award Ceremony


*subject to change